What do systematic reviews say?

Neuronavigation image‐guided surgery vs surgery

The review found no eligible studies for this question.

• Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

iMRI image‐guided surgery vs surgery

The review found no eligible studies for this question.

• Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐ALA image‐guided surgery vs surgery

The review found no eligible studies for this question.

• Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Intraoperative imaging technology to maximise extent of resection for glioma 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs no exercise

The review found no eligible studies for this question.

• Exercise interventions for adults with cancer receiving radiation therapy alone 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Weekly paclitaxel vs three‐weekly paclitaxel

It is very uncertain whether weekly paclitaxel changes overall survival compared with three‐weekly paclitaxel (very low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.94 [0.66, 1.33]
  2 studies · 263 participants
  Very low

175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel

175 mg/m2 paclitaxel showed no clear difference in overall survival compared with 250 mg/m2 paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.97 [0.77, 1.23]
  1 study · 330 participants
  Low

135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel

135 mg/m2 paclitaxel showed no clear difference in overall survival compared with 175 mg/m2 paclitaxel (low certainty).

• Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.96 [0.77, 1.19]
  1 study · 407 participants
  Low

Bevacizumab plus chemotherapy vs chemotherapy alone

Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.77 [0.62, 0.95]
  1 study · 452 participants
  Low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.9 [0.51, 1.6]
  1 study · 52 participants
  Low

Pazopanib plus lapatinib vs lapatinib

Pazopanib plus lapatinib may leads to higher overall survival compared with lapatinib (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 2.71 [1.16, 6.31]
  1 study · 117 participants
  Low

Pazopanib vs lapatinib

Pazopanib showed no clear difference in overall survival compared with lapatinib (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.96 [0.67, 1.38]
  1 study · 152 participants
  Low

Cediranib plus chemotherapy vs placebo plus chemotherapy

Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).

• Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
  HR 0.94 [0.53, 1.65]
  1 study · 69 participants
  Low

Daily conventionally fractionated radiotherapy vs supportive care

Daily conventionally fractionated radiotherapy probably leads to higher overall survival compared with no radiotherapy (supportive care alone) (moderate certainty).

• External beam radiation dose escalation for high grade glioma 2020 · Cochrane Headline outcomes only
  HR 2.01 [1.58, 2.55]
  4 studies · 397 participants
  Moderate

Hypofractionated radiotherapy vs daily conventionally fractionated radiotherapy

It is very uncertain whether hypofractionated radiotherapy changes overall survival compared with daily conventionally fractionated radiotherapy (very low certainty).

• External beam radiation dose escalation for high grade glioma 2020 · Cochrane Headline outcomes only
  HR 0.95 [0.78, 1.17]
  5 studies · 943 participants
  Very low

Hormone replacement therapy (HRT) vs no HRT

Hormone replacement therapy (HRT) may leads to lower overall survival compared with no HRT (low certainty).

• Hormone replacement therapy after surgery for epithelial ovarian cancer 2020 · Cochrane Headline outcomes only
  HR 0.71 [0.54, 0.93]
  3 studies · 350 participants
  Low

Intervention not reported

• Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage cervical… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

EGFR tyrosine kinase inhibitor (TKI) vs observation

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.99 [0.81, 1.2]
  1 study · 835 participants
  Low

Anti‐EGFR antibody plus chemotherapy vs chemotherapy alone

Anti‐EGFR antibody plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (moderate certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 0.93 [0.74, 1.18]
  4 studies · 658 participants
  Moderate

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy showed no clear difference in overall survival compared with chemotherapy alone (low certainty).

• Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
  HR 1.25 [0.8, 1.95]
  1 study · 129 participants
  Low

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery

It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes overall survival compared with stereotactic radiosurgery (very low certainty).

• Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
  HR 0.92 [0.48, 1.77]
  1 study · 64 participants
  Very low